241 related articles for article (PubMed ID: 34624192)
1. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
Ayala-Aguilera CC; Valero T; Lorente-Macías Á; Baillache DJ; Croke S; Unciti-Broceta A
J Med Chem; 2022 Jan; 65(2):1047-1131. PubMed ID: 34624192
[TBL] [Abstract][Full Text] [Related]
2. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
[TBL] [Abstract][Full Text] [Related]
3. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
[TBL] [Abstract][Full Text] [Related]
4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
5. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
6. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
7. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
[TBL] [Abstract][Full Text] [Related]
8. Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications.
Tamatam R; Mohammed A
Eur J Med Chem; 2024 Jun; 272():116441. PubMed ID: 38759455
[TBL] [Abstract][Full Text] [Related]
9. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
Latham BD; Geffert RM; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
[TBL] [Abstract][Full Text] [Related]
10. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
11. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
12. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract][Full Text] [Related]
15. The ins and outs of selective kinase inhibitor development.
Müller S; Chaikuad A; Gray NS; Knapp S
Nat Chem Biol; 2015 Nov; 11(11):818-21. PubMed ID: 26485069
[No Abstract] [Full Text] [Related]
16. An update of new small-molecule anticancer drugs approved from 2015 to 2020.
Liang X; Wu P; Yang Q; Xie Y; He C; Yin L; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B
Eur J Med Chem; 2021 Aug; 220():113473. PubMed ID: 33906047
[TBL] [Abstract][Full Text] [Related]
17. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
Shah RR; Roberts SA; Shah DR
Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
[TBL] [Abstract][Full Text] [Related]
18. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
19. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
20. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Das D; Hong J
Eur J Med Chem; 2019 May; 170():55-72. PubMed ID: 30878832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]